Complications, resource utilization, and cost of ABO-incompatible living donor kidney Ttransplantation

Transplantation

Volumn 82, Issue 2, 2006, Pages 155-163

  Schwartz, Jason ^a   Stegall, Mark D ^a,b   Kremers, Walter K ^a   Gloor, James ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

ABO incompatible; Cost; Kidney transplantation

Indexed keywords

ALBUMIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; ATELECTASIS; BLOOD GROUP ABO INCOMPATIBILITY; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DEHYDRATION; DEPRESSION; DESENSITIZATION; DIALYSIS; DISEASE EXACERBATION; DISORDERS OF ACID BASE BALANCE; DRUG BLOOD LEVEL; FALSE ANEURYSM; FEMALE; GRAFT SURVIVAL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART INFARCTION; HEMATOMA; HERNIA; HUMAN; HYPERGLYCEMIA; HYPERVOLEMIA; KIDNEY ALLOGRAFT; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVING DONOR; LYMPHOCELE; MALE; MENTAL DISEASE; MICTURITION DISORDER; PLASMAPHERESIS; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RASH; RENAL ARTERY ANEURYSM; RESOURCE ALLOCATION; RESPIRATORY FAILURE; SEROMA; STATISTICAL ANALYSIS; TACHYCARDIA; THROMBOCYTOPENIA; TOXICITY; URETER STRICTURE; URINE INCONTINENCE; VASCULAR DISEASE; WOUND INFECTION;

ABO BLOOD-GROUP SYSTEM; ADULT; BLOOD GROUP INCOMPATIBILITY; COST OF ILLNESS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MINNESOTA; POSTOPERATIVE COMPLICATIONS; RESOURCE ALLOCATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33746414227     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000226152.13584.ae     Document Type: Article

References (34)

1. Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation 2004; 78(5): 635.
2. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75(7): 971.
3. Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABO-incompatible living kidney transplantation. Transplantation 1998; 65: 224.
4. Alexandre GPJ, Squifflet JP, De Bruyere M, et al. Present experience in a series of 26 ABO-incompatible living donor allografts. Transplant Proc 1987; 19(6): 4525.
5. Stegall MD, Larson TS, Prieto M, et al. Living-donor kidney transplantation at Mayo Clinic - Rochester. Clin Transpl 2002: 155-61.
6. Heimback JK, Taler SJ, Prieto M, et al. Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. Am J Transplant 2005; 5(5): 1057.
7. Bergstrahl E, Kosanke J, Jacobsen S. Software for optimal matching in observational studies. Epidemiology 1996; 7: 331.
8. Lewis MS. Factors in cardiac risk stratification of candidates for renal transplant J Cardiovasc Risk 1999; 6(4): 251.
9. Lindholm A. Ischemic heart disease - major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60(5): 451.
10. Reis MA. Causes of death in renal transplant recipients: a study of 102 autopsies from 1968 to 1991. J R Soc Med 88(1): 24.
11. Lemmers MJ. Major role for arterial disease in morbidity and mortality after kidney transplantation in diabetic recipients. Diabetes Care 1991; 14(4): 295.
12. Lewis, MS, Wilson RA, Walker KW, et al. Validation of an algorithm for predicting cardiac events in renal transplant candidates. Am J Cardiol 2003; 89(7): 847.
13. Jindahl RM, Zawada ET. Obesity and kidney transplantation. Am J Kid Dis 2004; 43(6): 943.
14. Marks WH, Florence LS, Chapman PH, et al. Morbid obesity is not a contraindication to kidney transplantation. Am J Surg 2004; 187: 635.
15. Johnson DW. The effect of obesity of renal transplant outcomes. Transplantation 2002; 74(5): 600.
16. Winters JL, Gloor JM, Pineda AA, et al. Plasma exchange conditioning tor ABO-incompatible renal transplantation. J Clin Apheresis 2004; 19(2): 79.
17. Alkhunaizi AM, De Mattos AM, Barry JM, et al. Renal transplantation accross the ABO barrier using A2 kidneys. Transplantation 1999; 67(10): 1319.
18. Nelson PW, Landreneau MD, Luger AM, et al. Ten-year experience in transplantation of A2 kidneys into B and O recipients. Transplantation 1998; 65(2): 256.
19. Sorensen JB, Grant WJ, Belnap LP, et al. Transplantation of ABO group A2 kidneys from living donors into group O and B recipients. Am J Transplant 2001; 1: 296.
20. Fidler ME, Gloor JM, Lager DJ, et al. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant 2004; 4(1): 101.
21. Wagner JL, Alberts SR, Sloan JA, et al. Incremental costs of enrolling cancer patients in clinical trials: a population-based study. J Natl Cancer Inst 1999; 91: 847.
22. Long KH, Bannon MP, Zietlow SP, et al. A prospective randomized comparison of laparoscopic appendectomy with open appendectomy: clinical and economic analyses. Surgery 2001; 129: 390.
23. Young-Fadok TM, Hall Long IC, McConnell EJ, et al. Advantages of laparoscopic resection for ileocolic Crohn's disease. Improved outcomes and reduced costs. Surg Endosc 2001; 15: 450.
24. Leibson CL, Katusic SK, Barbaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/ hyperactivity disorder. JAMA 2001; 285: 60.
25. Cordera F, Long KH, Nagorney DM, et al. Open versus laparoscopic splenectomy for idiopathic thrombocytopenic purpura: clinical and economic analysis. Surgery 2003; 134: 45.
26. Huddleston JM, Long KH, Naessens JM, et al. Medical and surgical comanagement after elective hip and knee arthroplasty. A randomized, controlled trial. Ann Int Med 2004; 141: 28.
27. Bryan CR, Winklhoer FT, Murillo D, et al. Improving access to kidney transplantation without decreasing graft survival: long term outcomes of blood group A2/A2B deceased donor kidney in B recipients. Transplantation 2005; 80: 75.
28. U.S. Renal Data System, USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute ot Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004.
29. Schnitzler MA, Hollenbeak CS, Cohen DS, et al. The economic implications of HLA matching in cadaveric renal transplantation. N Engl J Med 1999; 341(19): 1440.
30. Isaacs R. Optimal immunosuppression: a case of the haves and have nots? Am J Kidney Dis 2001; 37(1): 161.
31. Yen EF, Hardinger K, Brennan DC, et al. Cost-effectiveness of extending Medicare coverage ot immunosuppressive medications to the life of a kidney transplant. Am J Transplant 2004; 4(10): 1703.
32. Matas AJ, Schnitler M. Payment for living donor (vendor) kidneys: a cost-effectiveness analysis. Am J Transplant 2003; 4: 216.
33. Segev DL, Gentry SE, Warren DS, et al. Kidney paired donation and optimizing the use of live donor organ. JAMA 2005; 293: 1883.
34. Montgomery RA, Zachary AA, Ratner LE, et al. Clinical results from transplanting incompatible live donor kidney donor/recipient pairs using kidney paired donation. JAMA 2005; 294: 1665.